Vectra for Rheumatoid Arthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if a blood test called Vectra can manage rheumatoid arthritis (RA) more effectively than usual care. Vectra examines specific blood markers to predict disease progression. Participants will either have their treatment guided by Vectra results or follow standard care without the test. Suitable candidates have RA, are currently on RA medication, and are open to adjusting their treatment plan if necessary. As a Phase 2 trial, this research measures Vectra's effectiveness in an initial, smaller group, providing participants an opportunity to contribute to innovative RA management strategies.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but you must not be taking an anti-IL-6R drug. You should be on a non-biologic or biologic DMARD for at least 3 months before the trial.
What prior data suggests that the Vectra test is safe for guiding treatment decisions in rheumatoid arthritis?
Research has shown that the Vectra DA test is easy to handle because it is a simple blood test. This test checks 12 substances in the blood to help predict the progression of rheumatoid arthritis. No reports of side effects exist from the test itself, as it only involves drawing blood.
While Vectra DA does not directly treat rheumatoid arthritis, it aids doctors in determining the best treatment, leading to better disease management. The test effectively predicts disease activity, helping to prevent joint damage and disability. Overall, Vectra DA serves as a safe and helpful tool for managing rheumatoid arthritis.12345Why are researchers excited about this trial?
Researchers are excited about using Vectra DA in rheumatoid arthritis treatment because it offers a personalized approach to care. Unlike the standard treatments, which may include methotrexate, TNF inhibitors, or corticosteroids, Vectra DA provides a specific score that helps physicians tailor treatment decisions based on the individual's disease activity. This targeted method could lead to more effective and efficient management of the condition, potentially improving outcomes and quality of life for patients.
What evidence suggests that the Vectra test is effective for guiding treatment decisions in rheumatoid arthritis?
Research has shown that the Vectra DA test can help manage rheumatoid arthritis (RA) by predicting disease progression. In this trial, the Guided-Care Arm will use the Vectra score to guide treatment decisions. This score examines 12 different blood markers and aligns well with traditional methods of measuring RA activity. It can predict the likelihood of disease worsening, aiding doctors in making informed treatment choices. Another study confirmed that Vectra's scores closely match the risk of joint damage seen in X-rays. Overall, using Vectra DA can tailor treatments to control RA, potentially improving patient outcomes. Participants in the Usual Care Arm will receive standard treatment without the Vectra score.678910
Who Is on the Research Team?
Jeffrey R. Curtis, MD, MPH
Principal Investigator
University of Alabama at Birmingham
Elena Hitraya, MD
Principal Investigator
Consultant
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Vectra-guided care or usual care for rheumatoid arthritis
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Vectra DA
Find a Clinic Near You
Who Is Running the Clinical Trial?
Myriad Genetic Laboratories, Inc.
Lead Sponsor
Sequenom, Inc.
Lead Sponsor
Laboratory Corporation of America
Industry Sponsor